2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-186169A
    S-MDDMA
    S-MDDMA is the S-enantiomer of (R,S)-MDDMA (HY-186169B), and mediates serotonin release from cells expressing SERT.
    S-MDDMA
  • HY-186169B
    (R,S)-MDDMA
    (R,S)-MDDMA is an MDMA analog that lacks the psychostimulant effects of its parent compound. (R,S)-MDDMA still retains partial serotonin-releasing activity.
    (R,S)-MDDMA
  • HY-186170A
    S-MDMA
    S-MDMA is an isomer of 4-methylenedioxymethamphetamine (MDMA) isomer. S-MDMA can promotes cortical neurons growth.
    S-MDMA
  • HY-186170B
    (R,S)-MDMA 859811-50-0 98%
    (R,S)-MDMA acts as a partial agonist of 5-HT2A, 5-HT2B and 5-HT2C receptors. (R,S)-MDMA belongs to psychoactive substances. (R,S)-MDMA exhibits antidepressant activity. (R,S)-MDMA can be used for research on mental disorders such as post-traumatic stress disorder and depression.
    (R,S)-MDMA
  • HY-19489S4
    (±)-Levomepromazine-13C,d3 98%
    (±)-Levomepromazine-13C,d3 ((±)-Methotrimeprazine-13C,d3) is the deuterium and 13C-labeled (±)-Levomepromazine (HY-19489). (±)-Levomepromazine ((±)-Methotrimeprazine) is the racemate of Levomepromazine (HY-B1693).
    (±)-Levomepromazine-13C,d3
  • HY-19733S1
    Lumateperone-d4 tosylate
    Lumateperone-d4 tosylate (ITI-007-d4 tosylate) is the deuterium labeled Lumateperone tosylate (HY-19733). Lumateperone (ITI-007) tosylate is a 5-HT2A receptor antagonist (Ki = 0.54 nM), a partial agonist of presynaptic D2 receptors and an antagonist of postsynaptic D2 receptors (Ki = 32 nM), and a dopamine D1 receptor modulator. Lumateperone tosylate has anticancer activity and can also be used in studies of psychiatric disorders such as schizophrenia.
    Lumateperone-d4 tosylate
  • HY-22437S1
    (±)-Darifenacin-d4 hydrobromide 2747914-16-3 98%
    (±)-Darifenacin-d4 (hydrobromide) is deuterium labeled (±)-Darifenacin. (±)-Darifenacin is the racemate of Darifenacin. Darifenacin is a selective M3 muscarinic receptor antagonist[1].
    (±)-Darifenacin-d4 hydrobromide
  • HY-34740S1
    Ethylmalonic acid-d5 66311-22-6 98.09%
    Ethylmalonic acid-d5 is the deuterium labeled Ethylmalonic acid (HY-34740). Ethylmalonic acid is a short-chain organic dicarboxylic acid. Ethylmalonic acid synergistically induces mitochondrial permeability transition (MP) with Ca2+, inhibits Mi-CK, and disrupts mitochondrial energy metabolism. Ethylmalonic acid can be used in the research of SCADD, EE and other genetic metabolic diseases characterized by EMA accumulation.
    Ethylmalonic acid-d5
  • HY-50898S5
    Lapatinib-13C,d7 1210608-87-9
    Lapatinib-13C,d7 (GW572016-13C,d7) is the deuterium and 13C-labeled Lapatinib (HY-50898). Lapatinib (GW572016) is a potent, orally active inhibitor of the ErbB-2 and EGFR tyrosine kinase domains with IC50 values against purified EGFR and ErbB-2 of 10.2 and 9.8 nM, respectively.
    Lapatinib-13C,d7
  • HY-70050AS
    Alosetron-d3 1190043-13-0 98%
    Alosetron-d3 is a deuterium labeled Alosetron. Alosetron is a serotonin 5HT3-receptor antagonist.
    Alosetron-d3
  • HY-70050CR
    Alosetron Hydrochloride (Standard) 122852-69-1 98%
    Alosetron (Hydrochloride) (Standard) is the analytical standard of Alosetron (Hydrochloride). This product is intended for research and analytical applications. Alosetron Hydrochloride (GR 68755C) is a potent and highly selective serotonin 5-HT3 receptor antagonist. Alosetron Hydrochloride is used for the research of irritable bowel syndrome (IBS). Alosetron blocks the fast 5HT3-mediated depolarisation of guinea-pig myenteric and submucosal neurons, with IC50 at ~55 nM. Alosetron Hydrochloride attenuates the visceral nociceptive effect of rectal distension in conscious or anaesthetised dogs. Anti-inflammatory effects.
    Alosetron Hydrochloride (Standard)
  • HY-76299S1
    Galanthamine-O-methyl-d3 1279031-09-2 98%
    Galanthamine-O-methyl-d3 is the deuterium labeled Galanthamine. Galanthamine is a potent acetylcholinesterase (AChE) inhibitor with an IC50 of 500 nM.
    Galanthamine-O-methyl-d3
  • HY-76570S1
    5-Hydroxymethyl Tolterodine-d14 formate 98%
    5-Hydroxymethyl Tolterodine-d14 (formate) is deuterium labeled (Rac)-5-Hydroxymethyl Tolterodine. (Rac)-5-Hydroxymethyl Tolterodine ((Rac)-Desfesoterodine), an active metabolite of Tolterodine, is a mAChR antagonist (Ki values of 2.3 nM, 2 nM, 2.5 nM, 2.8 nM, and 2.9 nM for M1, M2, M3, M4, and M5 receptors, respectively). (Rac)-5-Hydroxymethyl Tolterodine can be used for overactive bladder research.
    5-Hydroxymethyl Tolterodine-d14 formate
  • HY-76570S2
    (Rac)-5-Hydroxymethyl tolterodine-d5 2012598-78-4 98%
    (Rac)-5-hydroxymethyl Tolterodine-d5 ((Rac)-Desfesoterodine-d5; (Rac)-PNU-200577-d5) is deuterium-labeled (Rac)-5-Hydroxymethyl Tolterodine (HY-76570).
    (Rac)-5-Hydroxymethyl tolterodine-d5
  • HY-76657AR
    Alvimopan dihydrate (Standard) 170098-38-1 98%
    Alvimopan (dihydrate) (Standard) is the analytical standard of Alvimopan (dihydrate). This product is intended for research and analytical applications. Alvimopan dihydrate (ADL 8-2698 dihydrate) is a potent, selective, orally active and reversible μ-opioid receptor antagonist, with an IC50 of 1.7 nM. Alvimopan dihydrate has selectivity for μ-opioid receptor (Ki=0.47 nM) over κ- and δ-opioid receptors (Kis=100, 12 nM, respectively). Alvimopan dihydrate can be used for the research of postoperative ileus.
    Alvimopan dihydrate (Standard)
  • HY-77490AR
    1,3-Butanediol (Standard) 107-88-0 98%
    1,3-Butanediol (Standard) is the analytical standard of 1,3-Butanediol. This product is intended for research and analytical applications. 1,3-Butanediol, an ethanol dimer providing a source of calories for human nutrition. 1,3-Butanediol is converted in the body to β-hydroxybutyrate and has cerebral protective and hypoglycaemic effect.
    1,3-Butanediol (Standard)
  • HY-78327AS
    (S)-(+)-Modafinic acid-d5 98%
    (S)-(+)-Modafinic acid-d5 is deuterium labeled (S)-(+)-Modafinic acid.
    (S)-(+)-Modafinic acid-d5
  • HY-A0019AS
    Paliperidone palmitate-d4 1794685-21-4 98%
    Paliperidone palmitate-d4 (9-Hydroxyrisperidone palmitate-d4) is the deuterium labeled Paliperidone palmitate (HY-A0019A). Paliperidone palmitate is an orally effective competitive antagonist of dopamine D2 receptors and 5-hydroxytryptamine 2A (5-HT2A) receptors that can cross the blood-brain barrier. Paliperidone palmitate competitively inhibits the effects of dopamine and 5-hydroxytryptamine by binding to dopamine D2 receptors and 5-HT2A receptors, regulating the balance of the neurotransmitter system and thus exerting antipsychotic activity. Paliperidone palmitate is mainly used in the research field of schizophrenia.
    Paliperidone palmitate-d4
  • HY-A0042S1
    Rufinamide-15N,d2 1795037-48-7 98%
    Rufinamide-15N,d2 (CGP 33101-15N,d2) is the deuterium and 15N labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome.
    Rufinamide-15N,d2
  • HY-A0042S2
    Rufinamide-15N,d2-1 2012598-91-1 98%
    Rufinamide-15N,d2-1 (CGP 33101-15N,d2-1) is 15N- and deuterium-labeled Rufinamide (HY-A0042).Rufinamide (CGP 33101) is an orally active antiepileptic compound that inhibits Na+ current activation, inhibits neuronal hyperexcitability, and has anticonvulsant effects. Rufinamide is used in the study of Lennox-Gastaut syndrome.
    Rufinamide-15N,d2-1
Cat. No. Product Name / Synonyms Application Reactivity